Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Investing.com - Travere Therapeutics reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Travere Therapeutics announced earnings per share of $-1.09 on revenue of $53.50M. Analysts polled by Investing.com EPS of $-0.94 on revenue of $54.35M.
Travere Therapeutics 's are up 6.41% and is trading at $20.76 , still down 34.41% from its 52 week high of $31.65 set on Friday, December 31, 2021.
Travere Therapeutics follows other major Healthcare sector earnings this month
Travere Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar